The Efficacy of Spironolactone in Continuous Ambulatory Peritoneal Dialysis Patients with Hypokalemia: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200818005

Enrollment

Unknown

Registered

2020-08-18

Start date

2017-02-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A randomized controlled trial was conducted in CAPD patients with serum potassium <3.5 mEq/L. End stage renal disease&#44

Interventions

A randomized controlled trial was conducted in hypokalemic CAPD patients (serum potassium <3.5 mEq/L). They were assigned to receive 50 mg per day of spironolactone or placebo for 8 weeks. Serum potas

Placebo Comparator Drug,Placebo Comparator Drug

spironolactone 50 mg ,placebo

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: CAPD, age >18 years, serum k <3.5 mEq/L

Exclusion criteria

Exclusion criteria: exclusion criteria: PD-related peritonitis within 1 month, Chronicdiarrhea, severe nausia and vomiting

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of spironolactone 50 mg per day compare with placebo in CAPD patients with 8 weeks Serum potassium level	—

Secondary

Measure	Time frame
Safety profile 4 and 8 week Serum potassium level	—

Countries

Thailand

Contacts

Public ContactNaowanit Nata

Division of Nephrology

Naowanitnata2017@gmail.com662-6444676

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026